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Metallo--lactamases (MBLs) are of increasing clinical significance; the development of clinically useful MBL inhibitors is chal-
lenged by the rapid evolution of variant MBLs. The Verona integron-borne metallo--lactamase (VIM) enzymes are among the
most widely distributed MBLs, with >40 VIM variants having been reported. We report on the crystallographic analysis of
VIM-5 and comparison of biochemical and biophysical properties of VIM-1, VIM-2, VIM-4, VIM-5, and VIM-38. Recombinant
VIM variants were produced and purified, and their secondary structure and thermal stabilities were investigated by circular
dichroism analyses. Steady-state kinetic analyses with a representative panel of -lactam substrates were carried out to compare
the catalytic efficiencies of the VIM variants. Furthermore, a set of metalloenzyme inhibitors were screened to compare their
effects on the different VIM variants. The results reveal only small variations in the kinetic parameters of the VIM variants but
substantial differences in their thermal stabilities and inhibition profiles. Overall, these results support the proposal that protein
stability may be a factor in MBL evolution and highlight the importance of screening MBL variants during inhibitor develop-
ment programs.
Antibiotic resistance is a formidable threat to society; each year,an estimated 2 million people are infected with antibiotic-
resistant bacteria in the United States alone, resulting in 23,000
deaths (1). -Lactam antibiotics remain of immense clinical im-
portance in the treatment of bacterial infections, but resistance
increasingly compromises their clinical use. The most important
mechanism of resistance to -lactam antibiotics is mediated by
-lactamases, which catalyze -lactam hydrolysis, thus inactivat-
ing the antibiotics (Fig. 1). -Lactamases are broadly divided into
four classes: those in classes A, C, and D employ a hydrolysis
mechanism involving a nucleophilic serine residue, while class B
comprises the metallo--lactamases (MBLs), which employ metal
ions in catalysis (2). Although, to date, the serine enzymes have
been the most clinically relevant -lactamases, MBLs are of in-
creasing clinical concern, in part due to their broad-spectrum ac-
tivities. MBLs catalyze the hydrolysis of virtually all classes of
-lactams, with monobactams being the exception (3, 4). Ac-
quired MBLs, encoded by DNA on mobile elements, have been
reported in multiple major Gram-negative pathogens, including
members of the Enterobacteriaceae and Pseudomonas and Acineto-
bacter species, making MBL-producing microorganisms a serious
public health concern (5–7). MBLs are divided into the B1, B2,
and B3 subgroups, with subgroup B1 MBLs having the most clin-
ical relevance. Recent years have seen the worldwide spread of
acquired subgroup B1 MBLs, most importantly the imipenemase
(IMP), Verona integron-borne metallo--lactamase (VIM), and
New Delhi metallo--lactamase (NDM) groups (8). Despite rela-
tively low amino acid sequence identity (9, 10), all identified MBLs
share an / sandwich fold as well as a conserved active site,
which binds two or, less commonly, one zinc(II) ion. The roles of
the zinc(II) ions in catalysis include substrate binding, activation
of “hydrolytic” water, and stabilization of reaction intermediates.
The active sites of the MBLs are characterized by mobile loops,
including a hydrophobic L3 loop (residues 60 to 67, according to
the standard class B -lactamase (BBL) numbering scheme [10])
and a hydrophilic L10 loop (residues 223 to 242), both of which
are involved in substrate binding (8, 11–13).
The VIM enzymes currently constitute one of the largest
groups of subgroup B1 MBLs, comprising 46 reported variants
(http://www.lahey.org/Studies/other.asp). They can be divided
into the VIM-1 (14), VIM-2 (15), VIM-7 (16), VIM-12 (17), and
VIM-13 (18) clusters based on amino acid similarities (19).
VIM-1 was first reported in 1999 in Italy (20), with the VIM-2
variant being identified shortly thereafter in France (21) and Italy
(22). VIM-4, differing from VIM-1 by one residue (Ser228Arg),
was later reported in Pseudomonas aeruginosa isolates in Greece
(23). VIM-5 was subsequently identified in Turkey in Klebsiella
pneumoniae and Pseudomonas aeruginosa isolates (24, 25) and was
later identified in Enterobacter cloacae isolates (26). VIM-38,
which differs from VIM-5 by a single substitution (Ala316Val),
was recently identified in Pseudomonas aeruginosa isolates in Tur-
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key (27). This conservative substitution at the C terminus (sec-
ond-to-last residue) is present in 50% of VIMs. The greatest
variability in amino acid sequence across the five VIM variants is
found in the N-terminal leader sequence and, to a lesser extent, in
the C-terminal residues (see Fig. S1 in the supplemental material).
VIM-2, one of the most widely reported MBLs, shares 90%
amino acid similarity with the VIM-1 cluster (28). VIM-5 and
VIM-38 belong to the VIM-1 cluster and differ from VIM-1 by 5
and 6 residues, respectively (Ala130Lys, His224Leu, Glu225Ala,
Ser228Arg, and Lys291Thr, with an additional Ala316Val substi-
tution for VIM-38). Both VIM-5 and VIM-38 contain His224Leu
and Ser228Arg substitutions relative to VIM-1; these residues are
positioned on the L10 loop and are proposed to influence the
substrate specificity of VIM variants (13, 29–32).
Unlike the serine--lactamases, as yet, there are no clinically
useful MBL inhibitors. The development of broad-spectrum MBL
inhibitors is challenging, in part because of structural variation
across (and even within) subclasses but also because of the re-
quirement for selective inhibition of bacterial MBLs over human
MBL-fold enzymes, some of which have important physiological
roles. The continued emergence of new MBL variants with altered
substrate selectivity presents a further challenge to inhibitor de-
velopment. Despite the increased number of reports of VIM vari-
ants, structural information is available for only five of these vari-
ants (VIM-2, VIM-4, VIM-7, VIM-26, and VIM-31), and
biochemical characterization has been carried out for 10 VIM
variants (15, 19, 30, 32, 33). Biochemical studies have reported
that VIM-5 manifests a level of carbapenemase activity similar to
those of VIM-1 and VIM-2 but with greater efficiency toward
imipenem than meropenem (26). However, as exemplified by
studies with NDM variants (34), it is desirable to compare the
activities of MBL variants under the same experimental condi-
tions. To date, the important question of whether all the clinically
relevant MBL variants are similarly inhibited has not been ad-
dressed.
Here, we report studies on the biochemical and biophysical
properties of VIM-4, VIM-5, and VIM-38, in comparison with
those of the VIM-1 and VIM-2 enzymes, carried out under the
same experimental conditions. We observe modest differences in
the kinetic parameters for -lactamase activities against a variety
of -lactam substrates; however, the results reveal clear differ-
ences in the thermal stabilities of the VIM variants, as recently
reported for NDM variants (34). Interestingly, the tested variants
show clear differences in their inhibition profiles, with one iso-
quinoline derivative selectively inhibiting VIM-5 and VIM-38
more potently than VIM-1, VIM-2, or VIM-4. Crystallographic
studies on VIM-5 reveal structural differences that rationalize the
observed differences in inhibition potency.
MATERIALS AND METHODS
Cloning and mutagenesis. DNA encoding full-length VIM-38, lacking its
N-terminal periplasmic signaling sequence, was cloned into the pET-28a
vector (Novagen) for the production of recombinant protein with an
N-terminal His6 tag (pET28a-blaVIM-38). Site-directed mutagenesis
(Ala316Val) was performed to generate VIM-5 using pET28a-blaVIM-38 as
a template. Insertion PCR was carried out to incorporate a cleavage site for
human rhinovirus 3C (HRV3C) protease into the N terminus of the
VIM-5 and VIM-38 sequences. Primers used for mutagenesis are listed in
Table S1 in the supplemental material.
For the production of N-terminally His6-tagged VIM-1, Escherichia
coli codon-optimized VIM-1 coding sequences were inserted into
pNIC28-Bsa4 by using standard procedures (35).
Protein production and purification. E. coli BL21(DE3) cells were
transformed with plasmids encoding VIM-1, VIM-5, and VIM-38 for
protein production. The cells were cultured in 2 TY medium supple-
mented with kanamycin (50 g/ml), until mid-log phase (optical density
at 600 nm [OD600] of 0.7) was reached. The production of the recom-
binant proteins was then induced by the addition of 0.1 mM isopropyl-
-D-1-thiogalactopyranoside (IPTG), and the cells were cultured for a
further 16 h at 18°C. Cells were harvested by centrifugation (7,000  g for
10 min) and lysed by sonication. Three-step protein purification was car-
ried out using nickel ion affinity chromatography followed by size exclu-
sion chromatography, as previously reported (34). The purified VIM-5
and VIM-38 proteins were incubated overnight at 4°C with His-tagged
HRV3C protease or with His-tagged tobacco etch virus (TEV) for VIM-1,
to remove the N-terminal His6 tag, and further purified by using a second
nickel ion affinity column to obtain the untagged enzymes. VIM-2,
VIM-4, and C-terminally His6-tagged VIM-1 were produced and purified
as previously described (19, 36, 37). The purity of the proteins was ascer-
tained by SDS-PAGE; mass spectrometric analysis under both denaturing
and nondenaturing conditions was used to verify the masses and metal
contents of the purified VIM-5 and VIM-38 enzymes (see Fig. S2 and S3 in
the supplemental material).
Analysis of secondary structure content and melting temperature.
Circular dichroism (CD) analyses were carried out using a Chirascan CD
spectrophotometer (Applied Photophysics) equipped with a Peltier tem-
perature-controlled cell holder. CD measurements were collected in the
range of 185 to 260 nm; spectra were baseline corrected and smoothed
using a Savitzky-Golay filter. Data were normalized at 207 nm to account
for differences in protein concentrations (38), and the estimation of sec-
ondary structure content was performed with Dichro Web (39) using the
CONTIN Analysis Programme (reference set 6) (40). Melting tempera-
tures (Tm) of the recombinant enzymes were determined by monitoring
temperature-induced changes in the CD signal at 222 nm. The tempera-
ture was increased by 1°C per min, and the CD signal was recorded at
temperatures ranging from 25°C to 92°C. The samples were then cooled
FIG 1 Outline scheme for MBL-mediated -lactam hydrolysis.
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from 92°C to 25°C at the same rate, and a CD spectrum of the refolded
proteins was determined. The activity of the enzymes was recorded before
thermal denaturation and after refolding by monitoring nitrocefin hydro-
lysis. The thermal denaturation data were fitted to a Boltzmann sigmoidal
curve by using GraphPad Prism 5.0 software. CD spectra and thermal
denaturation curves are shown in Fig. 2 and in Tables S2 and S3 in the
supplemental material.
Determination of kinetic parameters. The hydrolysis of a represen-
tative panel of -lactam substrates was monitored at their respective ab-
sorbance wavelengths. The wavelengths and extinction coefficients used
were previously described (34). The assays were carried out using 50 mM
HEPES buffer (pH 7.2) supplemented with 1 g/ml bovine serum albu-
min (BSA), 1 M ZnSO4, and 0.01% Triton X-100. In the case of VIM-1,
C-terminally His6-tagged VIM-1 was used for kinetic analyses. Note that
no differences were observed between the activities of untagged VIM-1
and C-terminally His6-tagged VIM-1 for the selected antibiotics (data not
shown). The initial rates were obtained from the changes in absorbance at
various substrate concentrations. Steady-state kinetic parameters (Km and
kcat) were determined by fitting the initial velocity data to the Michaelis-
Menten equation using GraphPad Prism 5.01 software (see Table S4 in the
supplemental material).
Inhibition assays. Inhibitors were prepared as reported previously
(36, 41). Enzyme-mediated hydrolysis of nitrocefin was monitored by
determining the changes in absorbance at 495 nm, as previously described
(36, 37). Residual activities were first determined at a 100 M inhibitor
concentration. For the determination of 50% inhibitory concentrations
(IC50s), the reporter substrate (nitrocefin) was used at near-Km values,
and the enzyme was preincubated with the inhibitors for 10 min at room
temperature prior to the addition of the substrate (42). The residual ac-
tivities were obtained at increasing inhibitor concentrations (0.2 to 2,000
M); the data were analyzed using GraphPad Prism 5.01 software.
NMR binding assays. Binding assays were carried out using 1H-edited
Carr-Purcell-Meiboom-Gill (CPMG) nuclear magnetic resonance
(NMR) analyses. Spectra were recorded by using a Bruker AVIII 600-MHz
NMR spectrometer equipped with a BB-F/1H Prodigy N2 cryoprobe using
3-mm Match NMR tubes (Cortectnet). The PROJECT-CPMG sequence
(90°x-[-180°y--90°y--180°y-]n-acq) was applied, and water suppres-
sion was achieved by presaturation. Data were collected with a sweep
width of 12,019 Hz, an acquisition time of 2.7 s, and a filter width of
125,000 s. Assays were conducted using 50 mM Tris-D11 (pH 7.5) supple-
mented with 0.02% NaN3 in 90% H2O and 10% D2O. Equilibrium disso-
ciation constant (KD) measurements for the reporter ligand (50 M thio-
mandelic acid) and inhibitors (0 to 300 M) were carried out as
previously reported (43). Data were processed with Bruker 3.1 software
and fitted by using Origin Pro8.5.1 (see Table S5 in the supplemental
material).
VIM-5 crystallography. Purified VIM-5 was crystallized using the sit-
ting-drop vapor diffusion method with 96-well, 3-subwell Intelliplates
(Art Robbins). Drops of 300 nl were obtained by adding a protein solution
(23 mg/ml) and the reservoir buffer at a 2:1 ratio (protein/reservoir).
Crystals formed in wells containing 0.1 M Tris buffer (pH 8.5), 25% poly-
ethylene glycol 3350 (PEG 3350), and 0.2 M NaCl. A cryoprotectant so-
lution was prepared by diluting the well solution with glycerol to a final
concentration of 25% (vol/vol) glycerol. An 10 drop volume of cryo-
protectant was then added to the top of a drop containing crystals, and the
crystals were harvested using a nylon loop, followed by plunging into
liquid nitrogen. Data were then collected for a single crystal at the Dia-
mond Light Source synchrotron beamline. Data were processed by using
XDS and CCP4-SCALA in XIA2 (44–46). Initial phases were obtained by
molecular replacement (MR) (47) using the PHASER (48) subroutine
within PHENIX (49, 50), with the structure of VIM-4 (Protein Data Bank
[PDB] accession number 2WRS) (51) as the search model. Crystallo-
graphic structure refinement was carried out by iterative rounds of model
building using WinCoot (52) and maximum likelihood restrained refine-
ment using PHENIX. Data collection and refinement statistics are given in
Table S6 in the supplemental material.
Protein structure accession number. Coordinates and structure fac-
tors for VIM-5 have been deposited in the PDB under accession number
5A87.
RESULTS
Recombinant VIM-1, VIM-2, VIM-4, VIM-5, and VIM-38 were
efficiently produced and purified to near homogeneity as deter-
mined by SDS-PAGE analysis (see Fig. S2 in the supplemental
material). The molecular masses of the recombinant proteins as
determined by liquid chromatography-mass spectrometry (LC-
MS) analyses were in close agreement with the theoretical values.
Data from nondenaturing electrospray ionization mass spectro-
metric analyses validated the identities of the VIM-5 and VIM-38
variants and were consistent with the binding of two metal (zinc)
ions for each of the purified proteins (see Fig. S3 in the supple-
mental material).
Biophysical characterization. To compare the secondary
structural content of the VIM variants, far-UV circular dichroism
(CD) analyses were carried out on the untagged recombinant pro-
teins. All five VIM variants exhibited very similar CD spectra, with
a slight deviation in ellipticity at lower wavelengths, indicating
that the amino acid substitutions do not cause major perturba-
tions in secondary structure (Fig. 2a).
We then carried out temperature-dependent CD spectroscopy
to investigate the relative thermal stability of the VIM variants,
because some substitutions in VIM and NDM MBLs have been
associated with variations in protein stability (28, 34). With the
exception of VIM-1 and VIM-4, the CD spectra of the cooled
samples were nearly identical to those obtained before heating.
FIG 2 Circular dichroism analyses comparing CD spectra at 25°C (a) and melting temperatures (b) of the tested VIM variants.
Differences in Stability and Inhibition of VIM MBLs
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For all the tested VIM variants, the refolded samples retained sub-
stantial activity (2-fold differences as judged by kcat/Km values),
indicating that proteins regained their native structure upon re-
folding (see Table S3 in the supplemental material). The observed
reversibility allowed further thermodynamic analysis to obtain
melting temperature (Tm) values. Significant differences in the Tm
values of the five VIM variants were observed. VIM-5 and VIM-38
were the most stable variants, with an apparent Tm of 	83°C,
which is 5°C higher than that determined for VIM-2 (78°C).
VIM-1 and VIM-4 were the least stable of the tested variants, with
apparent Tm values of 60°C and 64°C, respectively, which are
	20°C lower than those of VIM-5 and VIM-38 and 	14°C lower
than that of VIM-2 (Fig. 2b).
Functional properties of VIM variants. The hydrolytic activ-
ities of the VIM variants against a representative set of -lactam
substrates were then compared under similar assay conditions.
Overall, the tested variants showed relatively small differences in
their catalytic efficiencies toward the tested -lactam substrates,
with VIM-5 and VIM-38 showing very similar kinetic parameters
(Table 1). In some cases, differences in individual kinetic param-
eters were observed, sometimes contributing to changes (albeit
relatively small ones) in the overall hydrolytic efficiency as defined
by kcat/Km values. For instance, for VIM-1, the Km value for mero-
penem was 	6-fold higher than that for VIM-2, indicating a lower
affinity for this substrate. This difference was, however, counter-
balanced by high kcat values for VIM-1 (	7-fold higher than those
for VIM-2), resulting in similar kcat/Km values. Despite VIM-1 and
VIM-2 variants having similar Km values for imipenem (likely
within experimental error), VIM-2 exhibited higher kcat values,
resulting in a 6-fold increase in kcat/Km value compared to that for
VIM-1. Relatively high apparent Km values (	300 M) were re-
corded for all VIM variants with ampicillin, indicating a relatively
low affinity for this penicillin. Notably, VIM-5 and VIM-38 had
	10-fold-higher kcat values for cefoxitin than did VIM-1, result-
ing in a 	7-fold increase in kcat/Km values. Cephalothin and ni-
trocefin were efficiently hydrolyzed by all the tested VIM variants,
recording the highest kcat/Km values compared to those with the
other -lactam substrates. Ceftazidime was a poor substrate for
the variants, with kcat/Km values being 0.1 s

1/M for the tested
VIM variants. Apparent kinetic parameters were reported for cef-
tazidime and ampicillin hydrolysis, since the initial velocity re-
mained proportional to the substrate concentration up to 300 M
(see Table S4 in the supplemental material).
Inhibition of VIM variants. To investigate if the VIM variants
might manifest different degrees of inhibition, we screened a set of
compounds containing different potential metal-chelating motifs
(36, 41), including isoquinolines and pyridine-2-carboxylates, to
compare their inhibitory effects on the VIM variants. An interest-
ing result to emerge from this work was that the isoquinoline
derivative (compound 1) is a substantially better inhibitor of
VIM-5 and VIM-38 (IC50  2 M) by 	500-fold than VIM-1
(IC50 of 	1 mM). VIM-2 and VIM-4 also had 	40-fold-higher
IC50s (IC50s of 90 M and 200 M, respectively) with inhibitor 1
than did VIM-5 and VIM-38 (Table 2). The configuration of the
stereocenter of the inhibitor side chain is important with respect
to the degree of inhibition, with the (R)-enantiomer (compound
1) being a more potent inhibitor than the (S)-enantiomer (com-
pound 2) for all the variants, except for VIM-1, for which the
(S)-enantiomer (compound 2) was a more potent inhibitor. The
isoquinoline ring system is also apparently important, as the pyr-
idine-2-carboxylate derivative (compound 3) with an (R)-trypto-
phan side chain analogous to that of compound 1 inhibited all
VIM variants similarly and with only modest potency (Fig. 3).
Interestingly, VIM-4 showed IC50s similar to those of VIM-2 for
the tested compounds despite differing from VIM-1 by only one
residue (Ser228 in VIM-1 and Arg228 in VIM-4).
To validate the inhibition results, we carried out 1H CPMG
NMR binding assays (43). The NMR analyses showed a similar
trend, with both isoquinoline inhibitors 1 and 2 binding more
strongly to VIM-5 than to VIM-2 (see Table S5 in the supplemen-
tal material). The (R)-enantiomer (compound 1) was also shown
to be a stronger binder to VIM-2 (apparent KD [KD app]  180
M) than the (S)-enantiomer (compound 2) (KD app  330 M),
highlighting the importance of the configuration of the side-chain
stereocenter in the potency of inhibition.
Crystallographic analysis. To explore the structural features
contributing to the observed differences in inhibition of the VIM
variants, a crystal structure of recombinant VIM-5 was deter-
mined to a 1.5-Å resolution (P21 space group), having 2 molecules
per asymmetric unit. The overall fold of VIM-5 was almost iden-
tical to that described for the previously reported VIM-2 structure
(PDB accession number 4BZ3), with a root mean square distance
(RMSD) of 0.206 Å. The overall fold of VIM-5 has the canonical
MBL / sandwich structure, with two zinc(II) ions (3.5 Å
apart) being bound in the active site located in a shallow cleft
formed by the interface of the two -sheets (Fig. 4A). The pro-
posed nucleophilic hydroxide/water molecule bridges between
the two zinc(II) ions and is positioned 1.9 Å and 2.0 Å from Zn1
and Zn2, respectively. The zinc(II) ion coordination geometry is
similar to the coordination observed for VIM-2 (Fig. 4B) (53).
TABLE 1 Kinetic parameters for VIM-1, VIM-2, VIM-5, and VIM-38 with a representative panel of -lactam substrates
Substrate






VIM-1b VIM-2 VIM-5 VIM-38 VIM-1 VIM-2 VIM-5 VIM-38 VIM-1 VIM-2 VIM-5 VIM-38
Meropenem 130  20 20  4 70  10 30  4 50 7 20 10 0.40 0.30 0.30 0.30
Imipenem 60  10 30  4 60  6 150  20 30 100 60 90 0.50 3.30 1.00 0.60
Ampicillin 	1,000 	500 	1,000 380  80 120 180 230 170 0.10 0.40 0.20 0.40
Cefoxitin 170  50 40  10 320  60 230  60 30 50 460 340 0.20 1.30 1.40 1.50
Ceftazidime 180  60 120  20 340  80 430  140 3 2 4 4 0.02 0.02 0.01 0.01
Cephalothin 140  10 50  6 100  8 60  8 450 210 200 120 3.20 4.20 2.00 2.00
Nitrocefin 15  1 50  5 50  5 70  10 130 510 420 720 8.70 10.2 8.40 10.3
a Km values are reported as the means of data from three independent measurements  standard deviations. Apparent kinetic parameters are reported for ampicillin and
ceftazidime hydrolysis. Standard deviation values for kcat did not exceed 10%.
b C-terminally His6-tagged VIM-1 was used for kinetic analyses (36).
Makena et al.
1380 aac.asm.org March 2016 Volume 60 Number 3Antimicrobial Agents and Chemotherapy
 on N
ovem







Despite having identical sequences, the VIM-5 L3 loop was closer
to the active site than observed for VIM-2, as was reported previ-
ously for VIM-4 and VIM-31 (19, 32). It is also notable that a
4.8-Å shift in the carbonyl oxygen position of Ala231 was observed
in comparison to the VIM-2 structure (PDB accession number
4BZ3) (see Fig. S4 in the supplemental material).
DISCUSSION
Overall, the kinetic results reveal relatively small differences in the
catalytic efficiencies of the tested VIM variants (Table 1), the bio-
logical relevance of which, if any, requires further investigation.
VIM-5 was found to have activity toward carbapenems similar
that of VIM-1 and VIM-2, as was previously proposed (26).
VIM-5 and VIM-38 display very similar kinetic parameters, as
expected, given that they differ by 1 residue at position 316 (Ala
and Val in VIM-5 and VIM-38, respectively). This substitution at
the C terminus of the enzymes is conserved and present in 50%
of the reported VIM variants (http://www.lahey.org/studies/other
.asp#).
The hydrolytic efficiencies presented here are in agreement
with those reported previously for some of the substrates (e.g.,
VIM-2 hydrolyzes imipenem better than meropenem) (21) but
differ with regard to other substrates; e.g., in our study, VIM-5
hydrolyzes ceftazidime with a 10-fold-higher efficiency than that
previously reported (26). The discrepancies observed may be at-
tributed to differences in enzyme preparation and assay condi-
tions, emphasizing the need to carry out comparative kinetic stud-
ies under similar experimental conditions (see Table S7 in the
supplemental material for a comparison of our data with data
from previous studies).
The VIM variants tested in this study exhibited similar CD
spectra, implying that their secondary structures are not substan-
tially affected by the differences in their sequences (Fig. 2a). How-
TABLE 2 Inhibition of VIM variants by selected isoquinoline and pyridine-2-carboxylates
Inhibitor
IC50 (M) (KD app [M])
a
VIM-1 (H224, S228) VIM-2 (Y224, R228) VIM-4 (H224, R228) VIM-5 (L224, R228) VIM-38 (L224, R228)
1 	1,000 90 (180) 200 2 (140) 2
2 60 300 (330) 600 50 (180) 80
3 50 100 125 50 50
a IC50 determinations were performed in triplicate over a range of inhibitor concentrations from 0.2 to 2,000 M. KD app values were determined by
1H CPMG NMR experiments
(see Table S5 in the supplemental material).
FIG 3 Inhibition of VIM variants by selected inhibitors. RA, residual activity.
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ever, marked differences in the thermal stabilities of the variants
were observed, with VIM-5 and VIM-38 having the highest melt-
ing temperatures (84°C and 83°C, respectively) compared to
VIM-2 (78°C). VIM-1 (60°C) and VIM-4 (64°C) showed signifi-
cantly lower melting temperatures (Fig. 2b). These results are in
agreement with previously reported low melting temperatures for
VIM-4 (19). The results showing increased thermal stability of at
least some VIM variants is interesting, as we have observed similar
trends with NDM variants (34). As proposed in the case of the
NDM variants, it is possible that the increased thermal stabilities
of emergent MBL variants could reflect increased cellular life-
times, directly due to either the improved thermal stability or a
reduced propensity for proteolysis or aggregation (34). Thus, al-
though “evolutionary drift” cannot be ruled out and further work
is required, the increased thermal stability of some MBL variants
presents an interesting line of investigation.
Unlike the relatively small differences in kinetic parameters
observed, very clear differences were observed for the inhibition of
different VIM variants with some (but not all) types of inhibitors
tested (Fig. 3). These differences are most clearly exemplified by
the relatively low IC50s reported for VIM-5 and VIM-38 with iso-
quinoline compound 1 compared to those for VIM-1, VIM-2, and
VIM-4 (Table 2). A crystal structure of VIM-5 reveals interesting
active-site differences compared to VIM-2 and provides some
possible insights into the differences in the catalytic and inhibitory
profiles of the VIM variants (Fig. 4).
The substitutions at residue 224 (His, Tyr, and Leu in VIM-1/
VIM-4, VIM-2, and VIM-5/VIM-38, respectively), which is lo-
cated on the L10 loop, likely contribute to the differential inhibi-
tion profiles observed. Comparison of the crystal structures of the
VIM variants reveals that replacement of Tyr224, as in VIM-2,
with Leu224, as in VIM-5 and VIM-38, likely provides a more
spacious active site that may better accommodate the bulky tryp-
tophan side chains of the tested inhibitors, as reflected by the
increased inhibition of VIM-5 and VIM-38 by inhibitors 1 and 2.
The smaller side chain of Leu224 in VIM-5 also enables a “flip-
ping” of the main-chain carbonyl of Ala231, altering the entrance
to the active site and likely affecting inhibitor binding. Notably,
the main-chain flipping of Ala231 is also observed for other en-
zymes with Leu224, such as VIM-26 (30) (see Fig. S4 in the sup-
plemental material).
The bicyclic isoquinoline ring system of inhibitors 1 and 2 may
FIG 4 (A) Ribbon representation of the VIM-5 crystal structure (PDB accession number 5A87) showing its overall fold. Metal binding residues are shown in
white, and zinc ions are shown as gray spheres. The L3 and L10 loops are highlighted in blue and green, respectively. (B) Closeup view of Leu224, Ala225, and
Arg228 residues within the VIM-5 active site. Observed electron density (2Fo 
 Fc contoured to 1 ) is shown as gray mesh. (C) Comparison of structures for a
hydrolyzed benzylpenicillin (i), the thioenolate inhibitor ML302F (ii), and an isoquinoline inhibitor (iii) showing possible interactions with VIM MBLs. The
green atoms likely interact with the hydrophobic L10 loop, while the blue atoms indicate groups likely to interact with the hydrophobic L3 loop. The atoms in red
are proposed to interact with the metal center of the enzyme. (D) Superimposition of the VIM-2 (cyan) (PDB accession number 4PVO) and VIM-5 (pink) (PDB
accession number 5A87) structures showing the effect of substitutions at residues 224 and 225, as observed for VIM-2 and VIM-5, and showing the binding mode
of the thioenolate inhibitor ML302F (yellow) in the VIM-2 active site (54).
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interact with the hydrophobic residues on the mobile L3 loop
(residues 60 to 66) (15), leading to better binding than with pyri-
dine-2-carboxylate inhibitor 3 for VIM-5 and VIM-38. It is pro-
posed that VIM-2 residue Glu225 forms electrostatic interactions
that rigidify and partially neutralize the side chain of Arg228,
which interacts with the carboxylate of -lactam substrates (15,
19). The replacement of Glu225 with Ala225, as in VIM-5 and
VIM-38, may enable more flexibility of the Arg228 side chain,
contributing to the observed differences in substrate/inhibitor
binding. Additionally, the hydrogen bond formed between the
Glu225 side chain and the main chain of Leu265 is disrupted in the
VIM-5 structure with the replacement of Glu225 with Ala225.
This may also have implications for substrate-inhibitor interac-
tions.
The overall results reveal that the tested VIM variants show
relatively small differences in their catalytic efficiencies with the
tested substrates, suggesting that changes in substrate selectivity
are not their sole evolutionary driving force, as was recently pro-
posed for NDM variants (34). We observed a marked difference in
thermal stability for the VIM variants, as observed for NDM vari-
ants, suggesting that this may reflect a selection pressure (34).
Perhaps most importantly, the results reveal that clinically ob-
served MBL variants can manifest different inhibition profiles, a
factor that we propose should be taken into account at an early
stage in inhibitor development programs.
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